{"code":"D68.51","type":"code","title":"Activated protein C resistance","codeAlso":[],"includes":[],"modern_v":"official26","codeFirst":[],"excludes1":["antiphospholipid syndrome (D68.61)","lupus anticoagulant (D68.62)","secondary activated protein C resistance (D68.69)","secondary antiphospholipid antibody syndrome (D68.69)","secondary lupus anticoagulant with hypercoagulable state (D68.69)","secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)","systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)","systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)","thrombotic thrombocytopenic purpura (M31.19)","abnormal coagulation profile NOS (R79.1)"],"excludes2":["coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1)","coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)"],"isBillable":true,"fyEffectivity":{"fy2026":true,"fy2027":true,"billableFy2026":true,"billableFy2027":true},"inclusionTerms":["Factor V Leiden mutation"],"useAdditionalCode":[],"clinicalDefinition":"Activated protein C resistance is a billable ICD-10-CM diagnosis code (D68.51). Inclusion terms: Factor V Leiden mutation. Excludes1 (not coded here): antiphospholipid syndrome (D68.61); lupus anticoagulant (D68.62); secondary activated protein C resistance (D68.69); secondary antiphospholipid antibody syndrome (D68.69); secondary lupus anticoagulant with hypercoagulable state (D68.69); secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.","officialDefinition":"Activated protein C resistance is a billable ICD-10-CM diagnosis code (D68.51). Inclusion terms: Factor V Leiden mutation. Excludes1 (not coded here): antiphospholipid syndrome (D68.61); lupus anticoagulant (D68.62); secondary activated protein C resistance (D68.69); secondary antiphospholipid antibody syndrome (D68.69); secondary lupus anticoagulant with hypercoagulable state (D68.69); secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69); systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0); systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312); thrombotic thrombocytopenic purpura (M31.19); abnormal coagulation profile NOS (R79.1). Excludes2 (not included here): coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1); coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3).","seventhCharacterInstructions":[],"workflowProtocols":[],"guidelines":{"whenToUse":[],"whenNotToUse":[],"commonBillingMistakes":[],"codeComparisons":[],"documentationChecklist":[]},"domainLandscape":{"summary":"Primary diagnostic domain and clinical landscape evaluation.","keyCategories":[],"diagnosticContinuum":"Progression continuum from acute presentation to resolution."},"children":[],"hierarchy":[],"relatedCodes":[],"relevantCPTCodes":[],"documentationTips":[],"caseStudies":[],"description":"","overview":""}